Figure 2.
Overview of Orai3 functional role in cancer cells. Orai3 expression has been reported to be up-regulated in different cancer cell types, including those from estrogen receptor-positive breast cancer (ER + BC), prostate cancer (PC), non-small cell lung cancer (NSCLC) cells, colorectal cancer (CC), pancreatic ductal adenocarcinoma (PDAC) as well as tipifarnib-sensitive acute myeloid leukemia and multiple myeloma (L and MM). Except in leukemia and multiple myeloma cells, Orai3 plays a relevant role in the development or maintenance of different cancer hallmarks, such as cell cycle progression and proliferation, apoptosis resistance and survival and migration and colony formation. In tipifarnib-sensitive leukemia and multiple myeloma cells Orai3-mediated Ca2+ influx is activated by tipifarnib leading to Ca2+ overload and loss of cell viability. PI3K, phosphatidylinositol 3-kinase; ARC channels, arachidonic acid-regulated calcium channels; ERK, extracellular signal-regulated kinase; sgk-1, serine/threonine-protein kinase-1; p53 degr., p53 degradation; cdk-4, cyclin-dependent kinase-4; CSC, cancer stem cells; HIP1/2α, hypoxia inducible factor 1/2α; ↑ means overexpression or activation and ↓ means inhibition.